12 Month Price Forecast For PGNY
Distance to PGNY Price Forecasts
PGNY Price Momentum
🤔 Considering Progyny (PGNY)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 12:27 PM UTC
PGNY Analyst Ratings & Price Targets
Based on our analysis of 11 Wall Street analysts, PGNY has a consensus that is neutral. The median price target is $19.00, with forecasts ranging from $17.00 to $22.00. Currently, there are 3 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
With PGNY currently trading at $14.86, the median price forecast suggests a 27.9% upside. The most optimistic forecast comes from Anne Samuel at JP Morgan, projecting a 48.0% upside, while Anne Samuel at JP Morgan provides the most conservative target, suggesting a 14.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PGNY Analyst Consensus
PGNY Price Target Range
Latest PGNY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PGNY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 2, 2024 | JP Morgan | Anne Samuel | Neutral | Downgrade | $17.00 |
| Nov 14, 2024 | Barclays | Sarah James | Overweight | Maintains | $17.00 |
| Nov 13, 2024 | Truist Securities | Jailendra Singh | Hold | Downgrade | $19.00 |
| Nov 13, 2024 | B of A Securities | Michael Cherny | Buy | Maintains | $21.00 |
| Nov 13, 2024 | Canaccord Genuity | Richard Close | Hold | Maintains | $17.00 |
| Oct 1, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $25.00 |
| Sep 20, 2024 | Canaccord Genuity | Richard Close | Hold | Maintains | $18.00 |
| Sep 19, 2024 | JMP Securities | Constantine Davides | Market Perform | Downgrade | $0.00 |
| Sep 19, 2024 | Leerink Partners | Michael Cherny | Market Perform | Maintains | $21.00 |
| Sep 19, 2024 | JP Morgan | Anne Samuel | Overweight | Maintains | $22.00 |
| Sep 19, 2024 | Jefferies | Glen Santangelo | Buy | Maintains | $24.00 |
| Sep 19, 2024 | Truist Securities | Jailendra Singh | Buy | Maintains | $26.00 |
| Sep 19, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $25.00 |
| Aug 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $37.00 |
| Aug 19, 2024 | JP Morgan | Anne Samuel | Overweight | Maintains | $31.00 |
| Aug 7, 2024 | BTIG | David Larsen | Neutral | Downgrade | $0.00 |
| Aug 7, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $37.00 |
| Aug 7, 2024 | Truist Securities | Jailendra Singh | Buy | Maintains | $33.00 |
| Aug 7, 2024 | JMP Securities | Constantine Davides | Market Outperform | Maintains | $31.00 |
| Aug 7, 2024 | Canaccord Genuity | Richard Close | Hold | Downgrade | $24.00 |
Progyny Inc (PGNY) Financial Data
Progyny Inc has a market capitalization of $1.34B with a P/E ratio of 26.2x. The company generates $1.14B in trailing twelve-month revenue with a 5.0% profit margin.
Revenue growth is +2.0% quarter-over-quarter, while maintaining an operating margin of +4.3% and return on equity of +12.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Progyny Inc (PGNY) Company Overview
About Progyny Inc
Provides fertility and family building benefits solutions.
Progyny, Inc. operates by offering comprehensive fertility benefits solutions to employers and their employees. The company generates revenue through its differentiated benefits plan design and personalized concierge-style support services, as well as through its integrated pharmacy benefits solution, Progyny Rx, which provides access to necessary medications. Additionally, Progyny offers reimbursement programs for services like adoption and surrogacy, creating a diverse income stream.
Founded in 2008 and headquartered in New York, Progyny was previously known as Auxogyn, Inc. and rebranded in 2015. The company focuses on a selective network of fertility specialists, enhancing the quality of care for its members.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
563
CEO
Mr. Peter Anevski CPA
Country
United States
IPO Year
2019
Website
www.progyny.comProgyny Inc (PGNY) Latest News & Analysis
Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders
1 day agoRobbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) for potential violations of securities laws and breaches of fiduciary duties by its officers and directors.
The investigation into Progyny's officers for potential securities law violations could lead to legal risks and financial liabilities, impacting investor confidence and stock performance.
Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
10 days agoJohnson Fistel, LLP is investigating Progyny, Inc. (NASDAQ: PGNY) for potential securities law violations related to misrepresentation and disclosure failures affecting investors.
The investigation into Progyny, Inc. for potential securities law violations could lead to significant financial repercussions, affecting stock value and investor confidence.
Progyny: Rating Downgrade On Uncertain Growth Outlook
17 days agoProgyny's rating is downgraded from buy to hold following disappointing Q3 2024 results, lowered FY24 guidance, and concerns over declining ART cycles and demand.
Progyny's downgrade signals reduced growth prospects and heightened uncertainty, impacting investor confidence. Disappointing Q3 results and lowered guidance suggest potential challenges ahead.
Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
25 days agoProgyny's stock fell 60% in 2024 after losing Amazon as a client. Q3 2024 showed weak revenue growth, declining margins, and lower EPS. Concerns about competition led to a sell recommendation.
Progyny's 60% stock drop, loss of a major client, and weak financials signal declining performance and competitive challenges, prompting a reevaluation of its investment viability.
Progyny, Inc. to Present at Jefferies London Healthcare Conference
29 days agoProgyny, Inc. (Nasdaq: PGNY) CEO Pete Anevski and CFO Mark Livingston will speak at the Jefferies London Healthcare Conference on November 19, 2024, at 8:00 a.m. GMT.
Progyny's leadership participation in a prominent healthcare conference signals potential insights into company strategy and performance, impacting investor sentiment and stock valuation.
These Analysts Slash Their Forecasts On Progyny Following Q3 Results
1 month agoProgyny, Inc. (PGNY) reported Q3 sales that missed expectations and provided FY24 revenue guidance below analyst estimates.
Progyny's disappointing Q3 sales and lower FY24 revenue guidance indicate potential growth challenges, likely leading to decreased investor confidence and a negative impact on stock performance.
Frequently Asked Questions About PGNY Stock
What is Progyny Inc's (PGNY) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Progyny Inc (PGNY) has a median price target of $19.00. The highest price target is $22.00 and the lowest is $17.00.
Is PGNY stock a good investment in 2025?
According to current analyst ratings, PGNY has 3 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.86. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for PGNY stock?
Wall Street analysts predict PGNY stock could reach $19.00 in the next 12 months. This represents a 27.9% increase from the current price of $14.86. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Progyny Inc's business model?
Progyny, Inc. operates by offering comprehensive fertility benefits solutions to employers and their employees. The company generates revenue through its differentiated benefits plan design and personalized concierge-style support services, as well as through its integrated pharmacy benefits solution, Progyny Rx, which provides access to necessary medications. Additionally, Progyny offers reimbursement programs for services like adoption and surrogacy, creating a diverse income stream.
What is the highest forecasted price for PGNY Progyny Inc?
The highest price target for PGNY is $22.00 from Anne Samuel at JP Morgan, which represents a 48.0% increase from the current price of $14.86.
What is the lowest forecasted price for PGNY Progyny Inc?
The lowest price target for PGNY is $17.00 from Anne Samuel at JP Morgan, which represents a 14.4% increase from the current price of $14.86.
What is the overall PGNY consensus from analysts for Progyny Inc?
The overall analyst consensus for PGNY is neutral. Out of 11 Wall Street analysts, 3 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $19.00.
How accurate are PGNY stock price projections?
Stock price projections, including those for Progyny Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
